CAS-ViewAlert

View Alert




Originator:		DHSC & NHS England and Improvement: Supply disruption alert
Issue date:		22-May-2020 13:24:13
This alert has been issued to:
		Care Trusts Mental Health Trusts Specialists Trusts Learning Disabilities Trusts Mental Health & Social Care Trusts Ambulance Trusts Mental Health & Learning Disabilities Trusts Acute Trusts Community Trusts
		MHRA (Medicines) Drug Alerts (Various Recipients) Other contacts Independent Healthcare Providers (registered with CAS) Clinical Commissioning Groups NHS Regional Offices NHS Foundation Trusts (England) - Medical Director NHS Foundation Trusts (England) - Chief Executive Special Health Authorities NHS Trusts (England) - Medical Director CMO Urgent Messages - Non-NHS Recipients on Public Health Link MHRA (Medicines) Drug Alerts - Non-NHS Recipients Territorial CMOs in Northern Ireland, Scotland & Wales Regional Directors of Public Health CMO Urgent Messages - Recipients on Public Health Link Director of Public Health NHS Trusts (England) - Chief Executive DHSC Supply Disruption - Medicines
Action category:		Immediate Action
Title:		Supply Disruption Alert: Update - Neuromuscular blocking agents: atracurium, cisatracurium and rocuronium
Broadcast content:		This supply disruption alert update supersedes the update (SDA/2020/004(R)) issued on 16th April 2020. The supply position on rocuronium has now substantially improved. Therefore, Trusts can now use rocuronium as a first-choice neuromuscular blocking agent (NMBA) in all scenarios as they choose, unless there is a contraindication. This alert contains further information and advice on the management of affected patients. Given the links to covid-19 we have sent this alert to a broader mailing list than would usually receive a Supply Disruption Alert of this type. Please note that no response is required via the CAS website to this alert.
Additional information:		This alert is not relevant to Primary Care.
Alert reference:		SDA/2020/004(R)(U)
Attachments:		SDA_2020_004_R_U.pdf